Search hospitals > Manitoba > WINNIPEG
CancerCare Manitoba
Claim this profileWINNIPEG, Manitoba R3E 0V9
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Brain Tumor
Conducts research for Leukemia
Conducts research for Lymphoma
433 reported clinical trials
19 medical researchers
Summary
CancerCare Manitoba is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Cancer, Breast Cancer, Brain Tumor, Leukemia, Lymphoma and other specialties. CancerCare Manitoba is involved with conducting 433 clinical trials across 439 conditions. There are 19 research doctors associated with this hospital, such as Ashley Chopek, Issai M. Vanan, Kristjan Paulson, and Versha Banerji.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Ashley ChopekCancerCare Manitoba6 years of reported clinical research
Studies Cancer
Studies Neuroblastoma
28 reported clinical trials
75 drugs studied
Issai M. VananCancerCare Manitoba6 years of reported clinical research
Studies Cancer
Studies Neuroblastoma
25 reported clinical trials
69 drugs studied
Kristjan PaulsonCancerCare Manitoba7 years of reported clinical research
Studies Graft-versus-Host Disease
Studies Bronchiolitis Obliterans Syndrome
4 reported clinical trials
5 drugs studied
Versha BanerjiCancer Care Manitoba3 years of reported clinical research
Studies Lymphoma
Studies Chronic Lymphocytic Leukemia
4 reported clinical trials
8 drugs studied
Clinical Trials running at CancerCare Manitoba
Cancer
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Testicular cancer
Acute Myelogenous Leukemia
Wilms Tumor
Myelodysplastic Syndrome
Breast Cancer
Neuroblastoma
Brain Tumor
Chemotherapy
for Cancer
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Recruiting2 awards Phase 326 criteria
Pembrolizumab
for Advanced Cancers
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the parent study. Participants who were in the First Course Phase of study treatment with pembrolizumab or lenvatinib in their parent study will enter the First Course Phase of this study and complete up to 35 doses or more every 3 weeks (Q3W) or 17 doses or more every 6 weeks (Q6W) of study treatment with pembrolizumab or a pembrolizumab-based combination or lenvatinib according to arm assignment. Participants who were in the Follow-up Phase in the parent study (post-treatment or Survival Follow-up Phase) will enter the Survival Follow-up Phase of this study. Participants who were in the Second Course Phase in their parent study will enter Second Course Phase of this study and complete up to 17 doses Q3W or 8 doses Q6W of study treatment with pembrolizumab or a pembrolizumab-based combination according to arm assignment. Any participant originating from a parent trial where crossover to pembrolizumab was permitted upon disease progression may be eligible for 35 doses as Q3W or 17 doses Q6W of pembrolizumab (approximately 2 years), if they progress while on the control arm and pembrolizumab is approved for the indication in the country where the potential eligible crossover participant is being evaluated.
Recruiting2 awards Phase 34 criteria
Triptorelin
for Cancer
This phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with an alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damage to the ovaries. If the ovaries are not working well or completely shut down, then it will be difficult or impossible to get pregnant in the future. Triptorelin works by blocking certain hormones and causing the ovaries to slow down or pause normal activity. The triptorelin used in this study stays active in the body for 24 weeks or about 6 months after a dose is given. After triptorelin is cleared from the body, the ovaries resume normal activities. Adding triptorelin before the start of chemotherapy treatment may reduce the chances of damage to the ovaries.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at CancerCare Manitoba?
CancerCare Manitoba is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Cancer, Breast Cancer, Brain Tumor, Leukemia, Lymphoma and other specialties. CancerCare Manitoba is involved with conducting 433 clinical trials across 439 conditions. There are 19 research doctors associated with this hospital, such as Ashley Chopek, Issai M. Vanan, Kristjan Paulson, and Versha Banerji.
Where is CancerCare Manitoba located?
CancerCare Manitoba is situated at 675 McDermot Avenue, Winnipeg, MB, near the intersection of McDermot Avenue and William Avenue.
Who should I call to ask about financial aid or insurance network?
**CancerCare Manitoba Financial Assistance and Insurance Inquiries:**
- For financial assistance, contact the CancerCare Co-Payment Assistance Foundation at 800-813-HOPE (4673). They provide support for transportation, home care, child care, and pet assistance for those with a confirmed cancer diagnosis, undergoing active treatment, residing in the U.S. or Puerto Rico, and meeting Federal Poverty Limit guidelines.
- CancerCare's "Managing the Cost of Cancer" booklet and the Purpose in Planning Coping Circle Series - Part I workshop offer resources and tips for managing cancer care costs and financial planning.
- In Manitoba, the Canadian Cancer Society's Access to Care program offers treatment-related travel and accommodation assistance for eligible individuals. CancerCare Manitoba provides free counseling on Manitoba’s Insured Health Benefits.
- The Government of Canada supports cancer patients through Employment Insurance (EI), sickness benefits, caregiving benefits, tax deductions, and the Canada Pension Plan (CPP).
What insurance does CancerCare Manitoba accept?
CancerCare Manitoba is a provincially mandated cancer agency offering clinical services to both children and adults, covered under Manitoba Health for Manitoba residents. This coverage includes physicians' services, surgery, anaesthesia, x-ray, and laboratory services in approved facilities. For out-of-province and out-of-country care, Manitoba Health provides certain coverages, but additional health insurance is recommended to cover excluded services and potential extra charges.
What awards or recognition has CancerCare Manitoba received?
CancerCare Manitoba Hospital, located in Winnipeg, Manitoba, benefits from substantial funding provided by the CancerCare Manitoba Foundation, thanks to the generous support of Manitobans. This financial backing has facilitated the hospital in leading and participating in clinical trials, funding local cancer research, and enhancing care and services for patients. The hospital's Research Institute, supported by over 40 scientists, concentrates on a broad spectrum of inquiries related to cancer and blood disorders.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.